29452results about "Biological testing" patented technology

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of the free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

Described herein are systems and methods for analyzing biological samples. Including a method for processing an analyte, comprising providing a fluidic device comprising the analyte and one or more polymer precursors; selecting a discrete area within said fluidic device; providing an energy source in optical communication with fluidic device; and selectively supplying a unit of energy generated from the energy source to the fluidic device to generate a polymer matrix within the fluidic device, wherein the polymer matrix is within the discrete area or adjacent to the discrete area.

The present application provides a method for diagnosing and / or evaluating the presence or absence, severity or degree of the improvement of a retinal disease in a subject, which comprises determining and / or evaluating circulatory parameters, retinal function, retina morphology and / or visual relating quality of life (QOL).

NADP-dependent oxidoreductase compositions, and electrodes, sensors and systems that include the same. Analyte sensors include an electrode having a sensing layer disposed thereon, the sensing layer comprising a polymer and an enzyme composition distributed therein. The enzyme composition includes nicotinamide adenine dinucleotide phosphate (NAD(P)+) or derivative thereof, an NAD(P)+-dependent dehydrogenase; an NAD(P)H oxidoreductase; and an electron transfer agent comprising a transition metal complex.

NADP-dependent oxidoreductase compositions, and electrodes, sensors and systems that include the same. Analyte sensors include an electrode having a sensing layer disposed thereon, the sensing layer comprising a polymer and an enzyme composition distributed therein. The enzyme composition includes nicotinamide adenine dinucleotide phosphate (NAD(P)+) or derivative thereof, an NAD(P)+-dependent dehydrogenase; an NAD(P)H oxidoreductase; and an electron transfer agent comprising a transition metal complex.

NADP-dependent oxidoreductase compositions, and electrodes, sensors and systems that include the same. Analyte sensors include an electrode having a sensing layer disposed thereon, the sensing layer comprising a polymer and an enzyme composition distributed therein. The enzyme composition includes nicotinamide adenine dinucleotide phosphate (NAD(P)+) or derivative thereof; an NAD(P)+-dependent dehydrogenase; an NAD(P)H oxidoreductase; and an electron transfer agent comprising a transition metal complex.

Methods and kits are provided for diagnosing of neuropsychiatric syndromes concurrent with SLE (NPSLE) and for determining whether an SLE subject is at risk of developing a neuropsychiatric disease.

NADP-dependent oxidoreductase compositions, and electrodes, sensors and systems that include the same. Analyte sensors include an electrode having a sensing layer disposed thereon, the sensing layer comprising a polymer and an enzyme composition distributed therein. The enzyme composition includes nicotinamide adenine dinucleotide phosphate (NAD(P)+) or derivative thereof; an NAD(P)+-dependent dehydrogenase; an NAD(P)H oxidoreductase; and an electron transfer agent comprising a transition metal complex.

NADP-dependent oxidoreductase compositions, and electrodes, sensors and systems that include the same. Analyte sensors include an electrode having a sensing layer disposed thereon, the sensing layer comprising a polymer and an enzyme composition distributed therein. The enzyme composition includes nicotinamide adenine dinucleotide phosphate (NAD(P)+) or derivative thereof, an NAD(P)+-dependent dehydrogenase; an NAD(P)H oxidoreductase; and an electron transfer agent comprising a transition metal complex.

The approach presented here relates to an analysis device for analyzing a viscosity of a fluid. The analysis device comprises a detection device and a provisioning device. The detection device is formed to determine the viscosity of the fluid using at least one Doppler parameter of a Doppler spectrum of the fluid. The provisioning device is formed to provide or transmit a viscosity signal that represents the viscosity determined by the detection device.

NADP-dependent oxidoreductase compositions, and electrodes, sensors and systems that include the same. Analyte sensors include an electrode having a sensing layer disposed thereon, the sensing layer comprising a polymer and an enzyme composition distributed therein. The enzyme composition includes nicotinamide adenine dinucleotide phosphate (NAD(P)+) or derivative thereof; an NAD(P)+-dependent dehydrogenase; an NAD(P)H oxidoreductase; and an electron transfer agent comprising a transition metal complex.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

The present invention relates to a blood testing machine comprising a loading device, a retrieving device, a batching device, a transfer device, and a testing device. After a blood sample is collected, a blood collection tube and other materials are placed in the loading device. After the loading device loads the sample, the retrieving device clamps the blood collection tube and other materials on the loading device and moves them to a set position in the batching device. The blood in the blood collection tube is sampled by the batching device and the reagents required for the test are added to form a test specimen. The transfer device transfers the test specimen to the testing device for blood testing. Compared with the prior art, the present invention substantially automates the steps of blood testing, including sample transportation, sample reception and processing, on-board testing, and sample storage, greatly improving the accuracy and speed of testing.

Aspects of the present disclosure include methods for spectrally resolving light from fluorophores in a sample. Methods according to certain embodiments include detecting light with a light detection system from a sample having a plurality of fluorophores having overlapping fluorescence spectra and spectrally resolving light from each fluorophore in the sample with a generalized least squares algorithm. In some embodiments, methods include estimating the abundance of one or more of the fluorophores in the sample, such as on a particle. In certain instances, methods include identifying the particle in the sample based on the abundance of each fluorophore and sorting the particle. Methods according to some embodiments includes spectrally resolving the light from each fluorophore by calculating a spectral unmixing matrix for the fluorescence spectra of each fluorophore. Systems and integrated circuit devices (e.g., a field programmable gate array) for practicing the subject methods are also provided.

The invention provides an HCG and LH test paper identification method and system based on optical characteristics and a storage medium. The method comprises the following steps: firstly, collecting and generating a reflectivity curve of a test paper detection area and a quality control area; secondly, extracting a reflection characteristic value of a curve in a detection area for test paper validity verification, and entering a core identification stage if the test paper is qualified; preliminary judgment is carried out by calculating a similarity deviation value of a quality control area curve and an HCG / LH standard curve, when the deviation is significant, a preliminary recognition result is generated and enters a cross validation link, and a result is confirmed by comparing a reflection characteristic value with a dynamic threshold range; when the similarity deviation is not obvious or the cross validation is not passed, starting a pre-trained discrimination model to perform final arbitration; by constructing a quadruple judgment mechanism of validity verification, preliminary recognition, cross validation and model arbitration, the operation complexity and misjudgment risk of manual test paper type selection are overcome, and the automation degree of the detection process and the accuracy and reliability of the recognition result are improved.

Methods of deconvolving a feature profile of a physical system are provided herein. The present method may include: optimizing a regression between a) a feature profile of a first plurality of distinct components and b) a reference matrix of feature signatures for a second plurality of distinct components, wherein the feature profile is modeled as a linear combination of the reference matrix, and wherein the optimizing includes solving a set of regression coefficients of the regression, wherein the solution minimizes 1) a linear loss function and 2) an L2-norm penalty function; and estimating the fractional representation of one or more distinct components among the second plurality of distinct components present in the sample based on the set of regression coefficients. Systems and computer readable media for performing the subject methods are also provided.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The invention discloses a method for improving beef quality, an action mechanism and an experimental method, in a cattle body, vitamin A can activate the expression of EBF2 through an active metabolite RA of the vitamin A, and the EBF2 can inhibit the transcription process of CYP26B1 in a targeted manner to maintain the activity of a retinol signal channel, so that PPAR gamma and downstream lipid metabolism related genes thereof are activated, and the activity of the retinol signal channel is improved. Fatty acid transport and lipid accumulation in fat cells in the cattle muscle are promoted, fat deposition in the cattle muscle is promoted, and the beef quality is improved. By constructing the molecular network for regulating and controlling the formation of the fat in the cattle muscle, a complex regulation and control mechanism for controlling the fat deposition in the cattle muscle can be understood more deeply, a method for improving the beef quality based on regulating and controlling the vitamin A mediated key factor EBF2 is provided, and a new way is provided for improving the beef quality in a targeted manner.

There is proposed a method for detecting a presence of a fluorescence pattern type on an organ segment via immunofluorescence microscopy and digital image processing. The steps comprise: provision of the organ segment, incubation of the organ segment with a liquid patient sample, incubation of the organ segment with secondary antibodies which have been labelled with a fluorescent dye, acquisition of a fluorescence image of the organ segment in a colour channel corresponding to the fluorescent dye, and provision of the fluorescence image to a neural network. What takes place by means of the neural network is simultaneous determination of segmentation information through segmentation of the fluorescence image and, furthermore, of a measure of confidence indicating an actual presence of the fluorescence pattern type. What further takes place is determination, on the basis of the previously determined segmentation information, of at least one sub-area of the fluorescence image that is relevant to formation of the fluorescence pattern type, determination, on the basis of the previously determined at least one sub-area, of validity information indicating a degree of a validity of the measure of confidence, and output of the measure of confidence depending on the validity information.

The invention provides a feed fermentation parameter intelligent correction method based on the Internet of Things, and the method comprises the steps: carrying out the full-dimensional data collection from a microenvironment in a feed fermentation tank to a cross-regional macroenvironment, and generating a standardized data matrix; detecting communication time delay fluctuation characteristics based on the standardized data matrix, determining a fluctuation period and an amplitude range of a time delay abnormal point, and forming a time delay fluctuation characteristic spectrum; analyzing the influence of a raw material nutrition structure and logistics transportation time efficiency on the purity and concentration uniformity of metabolites through a regional differentiation regulation and control plan, and outputting associated feature distribution of quality control imbalance between regions; and updating an operation instruction of the feed fermentation equipment in real time according to the association feature distribution of the quality control imbalance between the regions, and obtaining equipment state operation feedback data after the operation instruction is updated.

Provided herein are, inter alia, methods for identifying subjects suffering from depression that will respond to treatment with an antidepressant.

The invention relates to the technical field of biological medicines, and particularly discloses an anti-human CD3 rabbit recombinant monoclonal antibody as well as a preparation method and application thereof. The antibody obtains anti-CD3 immune response by immunizing a rabbit, is obtained by combining single B cell sorting, gene cloning and a mammalian cell expression system, and has high affinity and good specificity. The antibody can effectively recognize CD3 positive T cells in human peripheral blood and can be applied to the fields of flow cytometry, immunohistochemistry, T cell function research and the like. Experimental results show that the antibody has the advantages of high titer, strong fluorescence signal, low background and the like, and is superior to the traditional murine anti-CD3 antibody. Amino acid sequences of light chain and heavy chain variable regions of the antibody are further obtained, and controllability and repeatability of antibody expression are achieved. The antibody has important scientific research value and industrial application prospect, and is suitable for various scenes such as T cell marker detection, immune state evaluation, immunotherapy auxiliary research and the like.

Methods and apparatus for obtaining representations of proteins and small molecule drugs for synthesis; wherein pre-trained mixed modality protein and natural language fusion models are further trained by supervised fine tuning using reasoning-oriented query—chain-of-thought (CoT) response pairs. The resulting reasoning-oriented neural network is then used to obtain representations of output proteins or small molecule drugs, in response to mixed modality reasoning-oriented input queries specifying conditions on the output. In one embodiment, the neural network is an autoregressive multicapitate transformer whose decoder output heads correspond to the represented modalities. The method returns mixed modality output representations of proteins or small molecule drugs for synthesis or manufacture.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody combination for detecting cat FGF23 protein and application. The invention provides a monoclonal antibody combination with high specificity and strong sensitivity aiming at cat FGF23 protein. The antibody combination comprises monoclonal antibodies 5A2 and 3A1. By designing and optimizing complementary determining region (CDR) sequences of heavy chain and light chain variable regions, CDR amino acid sequences are respectively shown as SEQ ID NO.1 to SEQ ID NO.12, and the antibody combination has excellent binding activity and detection specificity. A double-antibody sandwich ELISA detection method constructed on the basis of the antibody combination has relatively high sensitivity, and the accuracy of a detection result is remarkably improved.

The invention belongs to the technical field of biological medicines, and provides application of DRAM1 as a diagnosis and treatment target for resisting non-alcoholic fatty liver disease related hepatocellular carcinoma in preparation of a kit, a carrier and a medicine aiming at the problem of lack of effective treatment targets of NAFLD-related HCC. As a target spot for resisting the non-alcoholic fatty liver disease related hepatocellular carcinoma, the expression level of the DRAM1 in liver tissues of non-alcoholic fatty liver disease related hepatocellular carcinoma patients and mice is increased. According to the application disclosed by the invention, research is developed aiming at the effect of the DRAM1 in the generation and development of NAFLD-related HCC, the analysis of TCGA liver cancer queue data and a GSE164760 data set is taken as an entry point, the influence of the DRAM1 on the diagnosis and prognosis of the liver cancer is comprehensively analyzed, and verification is carried out through a mouse in-vivo experiment, so that a new thought and a new target spot are provided for clinical diagnosis and treatment of the liver cancer.

The present application provides a test kit and a POCT blood cell analyzer. The test kit includes a box body, a sealing ring, a microporous sheet, and a back pool body. The box body includes a front pool and a mounting cavity connected to the front pool; the sealing ring is arranged in the mounting cavity and is located on the side of the mounting cavity close to the front pool; the microporous sheet is provided with micropores that allow cells to pass through one by one; the microporous sheet is arranged in the mounting cavity and is located on the side of the sealing ring away from the front pool; the back pool body abuts against the side of the microporous sheet away from the sealing ring, and is used to fix the microporous sheet and the sealing ring on the box body; the back pool body is formed with a drainage cavity, and the front pool and the drainage cavity are connected through micropores. The test kit provided by the present application has a simple structure, is easy to assemble, and is conducive to the processing of the test kit.

Provided herein are methods for high-accuracy sequencing of polymeric analytes, such as peptides, using nanopores or nanogaps. A method of the present disclosure may comprise generating a modified amino acid from an amino acid of the peptide, translocating the modified amino acid through or adjacent to a nanopore, and identifying the modified amino acid.

The invention discloses an abdominal aortic aneurysm progress prediction method and system based on cross-modal knowledge distillation. The method comprises the following steps: collecting blood of a target object; the method comprises the following steps: detecting the concentration of blood protein fingerprint markers of blood of a target object, wherein the blood protein fingerprint markers comprise matrix metalloproteinase-12, calcitonin-related polypeptide-alpha, uromodulin, nerve injury induction protein-1, glycosylated hemoglobin A1c and fibroblast growth factor-9; carrying out abdominal aortic aneurysm risk calculation by calling Student-net of cross-modal knowledge distillation based on the blood protein fingerprint marker concentration; wherein the input of the Teaser-net of the cross-modal knowledge distillation comprises a CTA image feature and a pathological section feature, and a category probability vector output by the Student-net is aligned with a category probability vector output by the Teaser-net; and outputting the risk level of the abdominal aortic aneurysm and the probability of occurrence / progress / rupture of the abdominal aortic aneurysm in the preset year. And the development of the aortic aneurysm disease is accurately predicted.